GENTA INC. Neue trend zum letzten Mal ?

Na da bin ich ja mal gespannt.....

Genta Incorporated to Host Conference Call to Discuss Fourth Quarter 2010 Highlights and Financial Results
March 24, 2011

[webcast]

BERKELEY HEIGHTS, NJ – March 24, 2011 – Genta Incorporated (OTCBB: GNTA.OB) announced today that the Company will release its fourth quarter 2010 financial results on Wednesday, March 30, 2011.  Genta management will host a conference call and live audio webcast that morning to discuss the financial results at 8:00 am ET.

Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (973) 200-3973 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http//:www.genta.com/investorrelation/events.html.

Moin,Kann mir jemand sagen, ob mit dem letzten Punkt vielleicht die Genasense-Ergebnisse gemeint sind? Diese sollten doch in Q2/2011 kommen. Würde also passen!

http://www.sec.gov/Archives/edgar/data/880643/.../genta_8k-032511.htm
Item 8.01 Other Events.
The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 47,234,779.
The total outstanding number of March 2010 Warrants and December 2010 Warrants as of the date of this filing is 110,643,000.
The Company currently expects to release the survival data in April 2011.

Auf Xetra 800 Stück  :-)

Cool, bei Tradegate wurden 3 Stck. gehandelt (Umsatz ca. 6ct)  ;-))))

 

TooNice Stocks gibt einen neuen Überblick über Genta.

"TooNiceStocks Initiates Coverage on Genta Incorporated - A Long History for Long Awaited Data due early Q2 of 2011"

Read more: http://www.benzinga.com/press-releases/11/03/...ated-a-long-history-f

 

Trade gate wieder 78% plus.
Soweit ich das sehe wurden sage und schreibe 0 Stück gehandelt.

Genta - einfach "sensational"  

geht wieder los..............  

was geht da heute ab????????????ß

 

ist doch scheißegal!!!  

hier 589050 seid ihr besser aufgehoben ;-) spass beiseite...hab den einstieg verpasst :-( aber bei genta hab ich auch schon genug verloren,da spiel ich nicht mehr mit..
trotzdem viel glück!!!kann man hier gebrauchen  

haben sich heute verdoppelt

 

Genasense® Phase 3 trial results:  In April 2011, Genta expects to report final data on overall survival (OS) from AGENDA, the Company’s randomized, double-blind, Phase 3 trial of dacarbazine with or without Genasense® (oblimersen sodium) Injection in patients with advanced melanoma.  Formal followup on all patients concludes in March 2011, two years from randomization of the last patient.  While differences in early endpoints of overall response and progression-free survival favored the group treated with Genasense, those differences did not achieve statistical significance.  The Company believes that a statistically significant increase in OS would enable submission of applications for regulatory approval of Genasense in advanced melanoma during 2011.

Genasense® Phase 2 data in melanoma:  A Phase 2 trial of Genasense plus Abraxane® and Temodar® as 1st-line treatment of patients with advanced melanoma has yielded promising results.  Final response and survival data from this trial have been submitted for presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2011.

Tesetaxel Phase 3 program:  The Company is currently recruiting investigator sites for a proposed multinational, Phase 3, randomized study of tesetaxel in patients with advanced gastric (stomach) cancer.  Tesetaxel has received both Fast Track and Orphan Drug designations for this indication by the U.S. Food and Drug Administration (FDA).  The Company has completed the “Scientific Advice” process for this trial with the European Medicines Agency.  Discussions regarding this protocol have also been held with regulatory authorities in the U.S. and Japan.  The IND process has also been initiated in Korea and China.

Tesetaxel Phase 2 Program and Special Studies:  In the past 12 months, Genta has initiated a broad Phase 2 program in other priority diseases including breast, prostate, and bladder cancer, as well as melanoma.  Initial data from several of these trials have been submitted for presentation at ASCO.  The Company expects to present results from its weekly dose-ranging and pharmacokinetic study of tesetaxel at the ASCO meeting, and to advance this new schedule into an ongoing trial in women with advanced breast cancer.  Based on promising clinical results, the company will convene an expert advisory panel to identify a potential regulatory strategy for tesetaxel in breast cancer.

Ganite® Clinical Trials:  During 2010, the Company reported initial data from a clinical and pharmacokinetic study of Ganite® (gallium nitrate injection) to treat chronic lung infections with Pseudomonas aeruginosa.  Several preclinical studies have shown that gallium nitrate has potent anti-infective activity against certain drug-resistant bacteria.  The Company is supplying Ganite® at no charge for an ongoing clinical study in patients with cystic fibrosis who are susceptible to resistant bacterial infections, which is being jointly conducted by the University of Washington and University of Iowa.  The study is funded in part by FDA, the National Institutes of Health, and the Cystic Fibrosis Foundation.  The Company continues to supply Ganite® for a clinical trial in patients with advanced non-Hodgkin’s lymphoma who have relapsed from bone marrow transplantation.

Oral Gallium Compounds:  In 2010, Genta extended its internal research and development program on oral gallium-containing compounds.  The program goal is to isolate novel, patentable, orally bioavailable compounds that can achieve specific target plasma concentrations that are known to be active.  A number of compounds have completed initial animal testing.  The Company hopes to identify a lead compound from this group and to file an Investigational New Drug (IND) exemption with FDA during 2011.  Clinical work with such compounds will focus primarily on diseases associated with accelerated bone loss, with potential secondary anticancer indications.

Intellectual Property:  In the past 8 months, the Company has filed 5 patent applications on processes and intermediate compounds used in the manufacturing of tesetaxel.  In 2010, two U.S. patents were issued, and the Company has filed 2 new patent applications on compositions and therapeutic uses of novel oral gallium-containing compounds.

http://www.genta.com/Press_Releases/2011/...rporate_Developments.html

Genta auf plus 100 % oder mehr hochgezockt wird.
Wenn die Shorties zum Schluss covern müssen, ist hier Nichts ausgeschlossen.

Ist mir mal vor 2 Jahren glücklicherweise bei einem OTC Wert passiert; da waren zuerst
50 bis 60 % Plus und am Tagesschluss dann 235 % Plus ( von 0,025 $  auf 0,084 $ )
aufgerufen worden.

Man darf gespannt sein....  

um grobe übersetzung - bzw. zusammenfassung des inhaltes - danke

 

Jetzt fällt sie aber wieder recht ordentlich.

translate.google.de/translate

 

Sensationell.  

Alle 20 mio Stück wurden komplett durchgenudelt zum Sensationskurs con +/-3ct. Das schafft nur Genta....

Morgen wieder 2,5ct zu haben.

:-)

fast auf Tageshoch......wahnsinn und das bei GENTA!

Das geht morgen erstmal so weiter :)  

 

gab es zig dilutions und rs splits  

Ich kam gestern zu 0,034 € rein, zocke bis Freitag mit und kloppe Genta dann wieder
raus.
In Amerika müssen noch Millionen von Optionen in den Markt integriert werden, was nur bei
steigenden Kursen funktioniert.
Da wir gestern in USA fast auf Tageshoch geschlossen haben, gibt es heute nochmals
einen Schub nach oben und am Freitag machen die Amis dann Kasse.
Heute werden wir in Frankfurt bei 0,044 € eröffnen und bis 15:30 Uhr Richtung 5 Cent laufen.

Catch the wave, when you trade GENTA !

Gru$$
KH